Cold Laser Therapy Market Size, Share, Trends, and Growth Forecast 2025 - 2032

The global cold laser therapy market size is projected to reach USD 130.8 million in 2025 and attain a CAGR of 5.2% from 2025 to 2032, reaching USD 187.1 million by 2032. According to Persistence Market Research the growth is fueled by the increasing prevalence of chronic pain, musculoskeletal disorders, and sports injuries, coupled with the rising demand for non-invasive, drug-free treatment options.

According to the 2023 National Health Interview Survey (NHIS), 24.3% of U.S. adults reported chronic pain, with 8.5% experiencing high-impact chronic pain that limits daily activities.  This widespread condition imposes a significant economic burden, with pain-related healthcare costs in the U.S. estimated at $565 to $635 billion annually, according to a report published by the National Center for Biotechnology Information (NCBI) and PubMed Central (PMC). To address this, technological advancements such as multi-wavelength laser systems and home-use cold laser devices are improving treatment accessibility and effectiveness, potentially reducing long-term healthcare expenses.

Key Industry Highlights:

• The rising demand for non-invasive pain management and tissue repair solutions fuels the industry growth in the coming years.
• Cold laser therapy is increasingly used by athletes and physiotherapists for faster recovery from injuries and muscle fatigue.
• Continuous laser devices are expected to dominate the market, accounting for a higher share due to their consistent energy delivery, deeper tissue penetration, and widespread use in pain management and rehabilitation.
• Physical therapy, ultrasound therapy, shockwave therapy, and PRP injections remain strong competitors, influencing adoption rates of cold laser therapy in the pain management segment.
• North America is expected to hold higher share of the market in 2025, driven by increasing adoption of cold laser therapy for chronic pain management, regulatory approvals, and advancements in laser technology.

Driver - The Growing Prevalence of Chronic Pain Management Induces Need for Cold Laser Therapy

The rising prevalence of chronic pain and musculoskeletal disorders is a key highlight. An NIH study published recently highlights high rates of persistent pain among U.S. adults, fueling demand for non-invasive treatment options. In April 2024, Domer Technology launched advanced cold laser devices for both human and veterinary use, while in May 2024, APEX Brain Centers explored Low-Level Laser Therapy (LLLT) for brain health. The shift toward drug-free pain management and the effectiveness of cold laser therapy in reducing inflammation and promoting tissue repair accelerate its adoption in healthcare.

Restraint - Challenges in Adoption Amid Competing Modalities

The adoption of cold laser therapy faces restraints due to competition from well-established alternative treatments such as physical therapy, ultrasound therapy, shockwave therapy, and PRP (platelet-rich plasma) injections. These modalities are widely used in pain management and rehabilitation, often preferred due to greater clinical validation, broader insurance coverage, and physician familiarity. For instance, shockwave therapy, commonly used for musculoskeletal conditions such as plantar fasciitis and tendon injuries, has shown high success rates in promoting tissue regeneration and pain relief. Alternatively, PRP injections use patient’s platelets to accelerate healing have become increasingly popular for sports injuries and osteoarthritis further limits the penetration of cold laser therapy.

Opportunity- Rising Consumer Adoption of At-Home Cold Laser Treatments

Expanding home-use cold laser therapy devices presents a significant opportunity for market growth. The increasing availability of compact, user-friendly, handheld lasers drives consumer adoption beyond clinical settings. FDA-approved devices like Erchonia’s EVRL for pain management and iRestore hair growth laser for hair restoration highlight the potential of at-home treatments. As consumers seek convenient, non-invasive solutions, the demand for home-use cold laser therapy is expected to rise, creating new revenue streams for manufacturers, and expanding market reach.

Product Type Insights

Continuous laser devices are projected to lead the product segment in 2025, accounting for approximately 55.6% market share. Their dominance stems from the ability to deliver a steady and focused laser beam, allowing deep tissue penetration crucial for cellular repair and inflammation reduction. These devices are preferred by healthcare professionals due to their precise dosage control, ensuring consistent and reliable treatment outcomes.

A notable example is the FX 635 Laser, manufactured by Erchonia Corporation, which is FDA-cleared for chronic low back pain and heel pain treatment. The FX 635 uses continuous laser technology provides non-invasive pain relief by stimulating cellular function and reducing inflammation making it a preferred choice for pain management and rehabilitation. The effectiveness and versatility of continuous laser devices such as the FX 635 further solidifies positions them as the dominating technology.

Modality Insights

In 2025, handheld cold laser devices are projected to dominate the modality segment, capturing approximately 59.3% market share. Their portability and ease of use make them ideal for both clinical and home settings. For example, devices such as the TerraQuant Pro by Multi Radiance Medical features multiple applicators and adjustable settings, enhances treatment precision for localized pain and injuries.

The growing demand for convenient, non-invasive therapy solutions drives the preference for handheld devices over tabletop alternatives. While both are non-invasive, handheld devices offer greater flexibility, allowing practitioners and patients to easily target specific areas in remote regions. Their lightweight and compact design makes them more adaptable for use across different treatment environments, whereas tabletop models are typically restricted to clinical settings limiting their accessibility for home-based therapy.

North America Cold Laser Therapy Market

North America is projected to account for 43.3% of the global cold laser therapy market by 2025, driven by regulatory approvals and technological advancements. The FDA’s approval of the first cold ablative fiber laser in April 2022, developed by Acclaro Corporation with its UltraClear™ system, marked a key milestone, expanding applications in pain management, dermatology, and rehabilitation. Additionally, industry leaders like Multi Radiance Medical and Erchonia Corporation continue to introduce innovative cold laser devices, such as the TerraQuant Pro and FX 635, which are widely used in musculoskeletal therapy, sports medicine, and chronic pain relief. The increasing adoption of handheld and multi-wavelength laser systems further strengthens North America’s position as a key market for cold laser technology.

Europe Cold Laser Therapy Market

Europe is estimated to account for 23.3% market share in 2025 driven by advancements in medical laser technology and a growing preference for non-invasive treatments. The EU Medical Device Regulation (MDR) ensures high safety and efficacy, boosting adoption among healthcare providers.

The clinical trials in February 2024 validated cold laser therapy’s effectiveness, with a randomized controlled trial showing that LLLT significantly reduces post-endodontic pain, reinforcing its role in pain management. Government-backed initiatives further drive demand, with Germany, France, and the U.K. leading adoption in physiotherapy clinics, sports medicine centers, and hospitals. For example, Celluma Light Therapy, an LLLT device, received EU MDR certification, highlighting the region’s focus on safety and effectiveness.

Asia Pacific Cold Laser Therapy Market

The East Asia market is projected to attain 18.5% market share driven by rapid technological advancements and increasing adoption of laser-based medical treatments. China and India are leading this expansion, integrating cutting-edge laser technologies into healthcare. In November 2024, the establishment of the Chinese Association for Laser in Medicine and Surgery (CALMS) in Shijiazhuang marked a significant step in China’s commitment to advancing laser-based medical technologies, including cold laser therapy. Simultaneously, India's focus on innovation is evident in the development of Class 4 laser therapy machines, enhancing pain relief and rehabilitation treatments. These innovations, showcased at international medical exhibitions highlight the region's increasing adoption of cold laser therapy, positioning East Asia as a key growth hub in the global market.

Latin America Cold Laser Therapy Market

In Latin America, cold laser therapy also known as low-level laser therapy (LLLT) is gaining traction as a non-invasive treatment for various medical conditions. In Mexico, the Lyme Mexico Clinic highlights its benefits in tissue regeneration, mitochondrial energy production, improved circulation, and lymphatic drainage. Similarly, research from Brazil’s Optics and Photonics Research Center (CEPOF) identified LLLT as the most effective treatment for tinnitus, a condition affecting 750 million people worldwide, due to its anti-inflammatory properties and ability to enhance peripheral circulation. As more healthcare providers in Mexico, Brazil, and Argentina integrate laser-based therapies, Latin America continues to expand its adoption of cold laser technology for pain management, rehabilitation, and neurological treatments.

Middle East and Africa Cold Laser Therapy Market

The Middle East and Africa (MEA) region is emerging as a lucrative market for cold laser therapy, driven by the increasing demand for non-invasive pain management solutions and advancements in medical laser technology. January 2025 marked a significant step in expanding laser-based treatment options for chronic pain relief in Kenya with the introduction of MLS® Laser Therapy. In the UAE, leading healthcare facilities are incorporating low-level laser therapy (LLLT) for musculoskeletal disorders and rehabilitation, reflecting the region’s growing adoption of advanced therapeutic solutions. These developments underscore the MEA region's increasing role in the global market, making it a key area for technological expansion and clinical adoption.

The global cold laser therapy market is fragmented, with key players such as Multi Radiance Medical, Erchonia Corporation, THOR Photomedicine, and Bioflex Laser competing across various segments. The market includes a diverse range of handheld and tabletop laser devices. Technological advancements are driving improvements in treatment precision, accessibility, and user adoption.

Key Industry Developments

• In November 2024, LumiThera Inc. announced that the U.S. Food & Drug Administration (FDA) granted marketing authorization for its Valeda® Light Delivery System for treating dry age-related macular degeneration (AMD). The system uses photobiomodulation (PBM) therapy, targets ocular damage and disease, addressing one of the leading causes of central vision loss in individuals over 55 years of age in developed countries.
• In July 2024, DS Group acquired Meditech International Inc., which is a global leader in low-power laser therapy and operates a renowned laser therapy clinic using its BIOFLEX-branded products. The acquisition strengthens DS Group’s presence in the medical technology sector, expanding its portfolio in laser therapy solutions.
• In January 2024, Iridex Corporation launched its next-generation Iridex 532® and Iridex 577® Lasers in the U.S., coinciding with its 35th anniversary celebration. A global leader in laser-based medical systems for eye disease treatment, Iridex expanded its portfolio with these advanced platforms, reinforcing its commitment to innovative ophthalmic solutions.